NYMC Faculty Publications

Hydroxychloroquine, Qtc Prolongation and Risk of Torsades De Pointes

Author Type(s)

Resident/Fellow, Faculty

DOI

10.5114/amsad/169982

Journal Title

Archives of Medical Sciences. Atherosclerotic Diseases

First Page

e75

Last Page

e80

Document Type

Article

Publication Date

1-1-2023

Department

Medicine

Abstract

Hydroxychloroquine (HCQ) is a common medication used for the treatment of rheumatic diseases. As a result of its widespread use during COVID-19, there are increasing concerns about its cardiotoxicity. HCQ is known to cause QTc prolongation, and its long-term use has been associated with cardiomyopathy and conduction abnormalities. Despite reports of ventricular arrhythmia in COVID-19 patients taking HCQ, there have been reassuring data in approved indications. HCQ has been in use for several decades with a good safety profile. In addition to better disease control and prevention of flares, it is associated with decreased risk of cardiovascular diseases. But given its small risk of cardiotoxicity, clinicians should be aware of this effect and monitor patients for developing cardiac symptoms.

This document is currently not available here.

Share

COinS